He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy.

CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.

He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program.

He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.

Chairman and managing partner Antoine Papiernik tells us about the fund and how he expects to deploy it. Plus, the current state of European biotech.

He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific.

He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.

CEO Michael Henderson walks us through what will be a busy year for the company.

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.

He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026.